Logo
x

Search

Subscribe Now

patients

Vifor and Angion's ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant

Vifor and Angion's ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant

  • October 27, 2021
Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D

Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D

  • October 15, 2021
Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active U...

  • October 15, 2021
Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSCLC

Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSC...

  • October 14, 2021
Novartis Reports the US FDA and EMA Filing Acceptance of Beovu for Patients with Diabetic Macular Edema

Novartis Reports the US FDA and EMA Filing Acceptance of Beovu for Patients with Diabetic Macular Edema

  • October 14, 2021
Ipsen's Cabometyx + Opdivo Receive EC's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Ipsen's Cabometyx + Opdivo Receive EC's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

  • March 31, 2021
LEO Pharma Reports the Regulatory Submission of Enstilar to the NMPA for Treating Plaque Psoriasis

    LEO Pharma Reports the Regulatory Submission of Enstilar to the NMPA for Treating Plaque Psoriasis

    • September 27, 2024
    Alvotech Reports the Initiation of Confirmatory Trial of AVT16 (Biosimilar, Entyvio)

      Alvotech Reports the Initiation of Confirmatory Trial of AVT16 (Biosimilar, Entyvio)

      • September 25, 2024
      Insights+ Key Biosimilars Events of July 2024

        Insights+ Key Biosimilars Events of July 2024

        • August 1, 2024
        Redefining Care: Gunjan Sharma from The US Oncology Network in Conversation with PharmaShots

          Redefining Care: Gunjan Sharma from The US Oncology Network in Conversation with PharmaShots

          • July 31, 2024
          Insights+ Key Biosimilars Events of June 2024

            Insights+ Key Biosimilars Events of June 2024

            • July 4, 2024
            HUTCHMED Features the P-III (ESLIM-01) Study Data of Sovleplenib for Primary Immune Thrombocytopenia at EHA 2024

              HUTCHMED Features the P-III (ESLIM-01) Study Data of Sovleplenib for Primary Immune Thrombocytopenia at EHA 2024

              • June 17, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.